Navigation Links
Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
Date:11/19/2008

w products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Only the FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Further, the scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the FDA for the products. The products are not approved
'/>"/>

SOURCE Amgen
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
2. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
3. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
4. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
5. Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
6. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
7. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
8. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
9. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
10. Raptor Pharmaceuticals Provides Update on Targeting Platforms
11. New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 Prostate Oncology Specialists announces ... to educate men about new imaging technology destined ... prostate. Annually, a million men undergo random needle ... MRI (MP-MRI) of the prostate gland is non-invasive ... need to be fully informed of their alternatives. ...
(Date:9/17/2014)...  Rebiotix Inc. announced this morning that results of the ... (microbiota suspension) will be presented in two posters and a ... Philadelphia from October 8-12. PUNCH ... on Thursday, October 9, 2014: Poster: RBX2660 (microbiota ... Analysis of the PUNCH-CD Phase 2 Safety Study ...
(Date:9/17/2014)... and SAN JOSE, Calif. , ... has been named as a laureate of The Tech Awards ... applying technology to benefit humanity and spark global change. The ... Innovation, and presented by Applied Materials, Inc., selected Gradian as ... Photo - http://photos.prnewswire.com/prnh/20140917/146680 ...
Breaking Medicine Technology:Prostate Cancer Awareness Month - Stop Random Biopsies 2Prostate Cancer Awareness Month - Stop Random Biopsies 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4Gradian Health Systems Named A 2014 Laureate of The Tech Awards 2Gradian Health Systems Named A 2014 Laureate of The Tech Awards 3
(Date:9/17/2014)... (PRWEB) September 17, 2014 Final Cut Pro ... entitled ProBlue 5k from Pixel Film Studios. , “ProBlue 5k ... users video from good to epic,” said Christina Austin, CEO ... armature, ProBlue 5k is a definite game changer.” , ProBlue ... package for any filmmaker ! This footage compilation of ...
(Date:9/17/2014)... 2014 People who struggle to distinguish between ... http://www.perwickstrom.com and get the answer by reading Per ... out, is that a business plan and a business strategy ... commented Per Wickstrom. “The way I view it is that ... strategy which is part two.” , According to the ...
(Date:9/17/2014)... IL (PRWEB) September 17, 2014 The ... Pseudomonas aeruginosa infections allegedly caused by Non-Sterile Other-Sonic ... learn more about their options for legal recourse. Other-Sonic ... Drug Administration (FDA) in March 2012, after the product ... aeruginosa at William Beaumont Hospital in Royal Oak, Michigan ...
(Date:9/17/2014)... Dennis Thompson HealthDay Reporter ... in the womb to household chemicals known as phthalates ... Columbia University researchers reported in a new study. ... developing asthma between age 5 and 11 if their ... two phthalates (pronounced thal-ates), the researchers found. The two ...
(Date:9/17/2014)... FRISCO, Texas (PRWEB) September 17, 2014 ... (EV-D68) outbreak that is hospitalizing scores of infants, children ... Louisiana, says Dr. Kirk Mahon, medical director of Legacy ... , “There have been no reported cases of EV-D68 ... Oklahoma and Louisiana, that could change,” he said. “Implementing ...
Breaking Medicine News(10 mins):Health News:A New Plugin Entitled ProBlue 5k Was Released Today from Pixel Film Studios Exclusively for Final Cut Pro X 2Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 2Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 3Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 4Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4Health News:Legacy ER & Urgent Care Warns North Texans about Dangers of Enterovirus D68 2
... 17 (HealthDay News) -- Among long-term breast cancer survivors, those ... much higher rates of death due to heart disease, new ... Jan. 25 issue of the Journal of the American ... such as that practiced until the mid-1980s, increased the long-term ...
... birth weight in First Nations (North American Indian) babies are ... that occur from 4 weeks to 1 year of age), ... Canadian Medical Association Journal ) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj100837.pdf ... as a child being born above the 90th percentile relative ...
... By Steven Reinberg HealthDay Reporter , ... are taking common blood pressure medications called calcium channel ... blood pressure and possibly going into shock if they ... antibiotics, erythromycin and clarithromycin, if given to patients taking ...
... on the milk we drink, according to new research ... during a particularly poor UK summer and the following ... less beneficial fatty acids than in a more ,normal, ... organic milk could help overcome these problems. Organic ...
... HealthDay Reporter , SATURDAY, Jan. 15 (HealthDay News) -- ... the breathing tube that had been in place since she ... attack in Tucson that killed six people. The new ... the Associated Press . The breathing tube had been ...
... January 14, 2011The ongoing controversy about the appropriate ... be explored at the upcoming 19th Annual Congress ... DC. A provocative "Point-Counterpoint: The Mammography Controversy" will ... PhD, Visiting Professor of Radiology, Magee-Womens Hospital, University ...
Cached Medicine News:Health News:Breast Cancer Radiation Before 1984 Tied to Heart Disease 2Health News:High birth weight in First Nations babies linked to a higher risk of postneonatal death 2Health News:Some Antibiotics, Blood Pressure Meds a Bad Mix: Study 2Health News:Some Antibiotics, Blood Pressure Meds a Bad Mix: Study 3Health News:Choosing organic milk could offset effects of climate change 2Health News:Choosing organic milk could offset effects of climate change 3Health News:Choosing organic milk could offset effects of climate change 4Health News:Rep. Giffords Has Surgery to Replace Breathing Tube 2Health News:Rep. Giffords Has Surgery to Replace Breathing Tube 3Health News:Mammography controversy to be explored at 19th Annual Congress on Women's Health 2
For the quantitative in vitro determination of Microalbumin in urine....
Determination of the Thrombin Time by STA Analyzers. Freeze-dried human thrombin (1.5NIH units/mL) with calcium....
Determination of Activated Partial Thromboplastin Time (APTT) by STA Analyzers. Cephalin reagent with kaolin activator....
Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
Medicine Products: